Now showing items 1-11 of 11

    • Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2 

      Plotkin, Scott Randall; Merker, Vanessa; Halpin, Chris; Jennings, Dominique; McKenna, Michael John; Harris, Gordon J.; Barker, Frederick George (Ovid Technologies (Wolters Kluwer Health), 2012)
      Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up ...
    • Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients 

      Merker, Vanessa; Esparza, S.; Smith, M. J.; Stemmer-Rachamimov, Anat; Plotkin, Scott Randall (Alphamed Press, 2012)
      Background. Schwannomatosis is a recently recognized form of neurofibromatosis characterized by multiple noncutaneous schwannomas, a histologically benign nerve sheath tumor. As more cases are identified, the reported ...
    • Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas 

      Blakeley, Jaishri O.; Ye, Xiaobu; Duda, Dan Gabriel; Halpin, Chris F.; Bergner, Amanda L.; Muzikansky, Alona; Merker, Vanessa; Gerstner, Elizabeth Robins; Fayad, Laura M.; Ahlawat, Shivani; Jacobs, Michael A.; Jain, Rakesh K.; Zalewski, Christopher; Dombi, Eva; Widemann, Brigitte C.; Plotkin, Scott Randall (American Society of Clinical Oncology (ASCO), 2016)
      Purpose Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by bilateral vestibular schwannomas (VSs) resulting in deafness and brainstem compression. This study evaluated efficacy and ...
    • Health-related Quality of Life of Individuals With Neurofibromatosis Type 2 

      Merker, Vanessa; Bergner, Amanda L.; Vranceanu, Ana-Maria; Muzikansky, Alona; Slattery, William; Plotkin, Scott Randall (Ovid Technologies (Wolters Kluwer Health), 2016)
      Objective: To explore health-related quality of life (HRQoL) reported by individuals with neurofibromatosis type 2 (NF2) and to assess for correlations between HRQoL and objective measures of disease manifestations. Study ...
    • Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients 

      Plotkin, Scott Randall; Merker, Vanessa; Muzikansky, Alona; Barker, Frederick George; Slattery, William (Ovid Technologies (Wolters Kluwer Health), 2014)
      Objective: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment Study Design: Prospective study. Setting: ...
    • Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1 

      Merker, Vanessa; Murphy, Timothy P.; Hughes, J. Bryan; Muzikansky, Alona; Hughes, Mark Stephen; Souter, Irene C.; Plotkin, Scott Randall (Elsevier BV, 2015)
      Objective To examine the effect of patient and facility level factors on the success of preimplantation genetic diagnosis (PGD) in patients with neurofibromatosis 1 (NF1). Design Retrospective review. Setting Large ...
    • Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis 

      Smith, Miriam J.; Esparza, Sonia; Merker, Vanessa; Muzikansky, Alona; Bredella, Miriam A.; Harris, Gordon J.; Kassarjian, Ara; Cai, Wenli; Walker, James Anthony; Mautner, Victor F.; Plotkin, Scott Randall (Elsevier BV, 2013)
      Objectives Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in ...
    • Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system 

      Terry, Anna R.; Merker, Vanessa; Barker, Frederick George; Leffert, Lisa Rae; Bateman, Brian Thomas; Souter, Irene C.; Plotkin, Scott Randall (Elsevier BV, 2015)
      Neurofibromatosis type 2 (NF2), tuberous sclerosis (TS), and von Hippel-Lindau disease (VHL) are tumor suppressor syndromes characterized by multiple benign tumors of the peripheral and central nervous system.1 These tumors ...
    • Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature 

      Vranceanu, Ana-Maria; Merker, Vanessa; Park, Elyse Richelle; Plotkin, Scott Randall (Springer Nature, 2013)
      The aim of this study was to review the literature on quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis, and to identify the specific aspects of quality of life that ...
    • Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis 

      Merker, Vanessa; Bredella, Miriam A.; Cai, Wenli; Kassarjian, Ara; Harris, Gordon J.; Muzikansky, Alona; Nguyen, Rosa; Mautner, Victor F.; Plotkin, Scott Randall (Wiley-Blackwell, 2014)
      Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of ...
    • Understanding Relationships Between Autism, Intelligence, and Epilepsy: A Cross-Disorder Approach 

      van Eeghen, Agnies M; Pulsifer, Margaret Bigwood; Merker, Vanessa; Neumeyer, Ann; van Eeghen, Elmer E; Thibert, Ronald L.; Cole, Andrew James; Leigh, Fawn; Plotkin, Scott Randall; Thiele, Elizabeth Anne (Wiley-Blackwell, 2012)
      Aim As relationships between autistic traits, epilepsy, and cognitive functioning remain poorly understood, these associations were explored in the biologically related disorders tuberous sclerosis complex (TSC), ...